Winter 2027

Commercialized Product Development Engineer Co-op

Orthopedics

Posted on 8/21/2026

Deadline 9/6/26
Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

No salary listed

No H1B Sponsorship

Warsaw, IN, USA

Hybrid

Hybrid work in Warsaw, Indiana; reliable transportation to the site is required.

Bachelor's

Category
Mechanical Engineering (2)
,
Required Skills
Microsoft Office
3D Modeling
Excel/Numbers/Sheets

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • Completion of undergraduate freshman year at an accredited university.
  • Currently pursuing a bachelor's degree or equivalent experience in Mechanical Engineering, Biomedical Engineering, or a related field.
  • A cumulative GPA of 3.5 or higher is required.
  • Availability to work full-time, 40 hours per week, during the co-op session.
  • Availability for at least three alternating semester rotations or combined consecutive rotations is required.
  • Knowledge and experience with Microsoft Office software, including intermediate to advanced skills with Microsoft Excel and PowerPoint.
  • Only students who have completed at least their first year of college by the start of their first work rotation will be considered.
  • Reliable transportation to and from the Warsaw, Indiana site is required.
  • Candidates must be legally authorized to work in the United States and must not require current or future sponsorship for an employment visa.
  • Candidates must be permanently authorized to work in the United States and must not require sponsorship for an employment visa or green card now or in the future.
Responsibilities
  • Apply engineering analysis methods, design tools, and problem-solving approaches to resolve engineering questions, non-conformances, change assessments, and investigations involving products currently sold in the field.
  • Learn and apply aspects of the design control process, including identifying patient and regulatory needs, assessing development and design documentation, identifying and controlling risks, and reviewing additional functional or mechanical testing when required.
  • Understand engineering drawings and 3D modeling concepts and complete additional design work based on background and successful task completion.
  • Observe manufacturing operations and provide development engineering support for manufacturing improvement projects.
  • Interface with expert engineers and cross-functional business partners.
  • Work on sustaining joint reconstruction prosthetics currently on the market, including knee, hip, and shoulder products.
  • Travel up to 10% domestically and internationally if required.
Desired Qualifications
  • Confirmed leadership, hands-on work experience, and/or participation in campus or community service activities.
  • Ability to work independently on one or multiple projects under general direction and attention to detail.
  • Strong written and verbal interpersonal skills, including experience presenting to multidisciplinary audiences and attending in-person and teleconference team meetings.
  • Experience with 3D modeling and engineering drawings.
  • Participation in training courses and additional learning opportunities.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Q2 2026 sales rose 6.6% to $25.3 billion; guidance reached $101.1 billion.
  • Tremfya jumped 72.5% to $2 billion in Q2 2026, replacing lost Stelara revenue.
  • MONARCH QUEST 3 cleared FDA on August 17, 2026, strengthening lung-cancer robotics adoption.

What critics are saying

  • Stelara fell 55.7% in Q2 2026; biosimilars keep pressuring immunology through 2027.
  • The July 27, 2026 talc deal commits $5.5 billion and prolongs legal uncertainty.
  • MedTech trails Intuitive Surgical and Medtronic; OTTAVA faces commercialization delays and share loss.

What makes Johnson & Johnson unique

  • J&J spans pharma and MedTech, reducing dependence on any single patent cycle.
  • Tremfya, Darzalex, and Inlexzo drive 2026 growth after Stelara's decline.
  • MONARCH QUEST 3 and OTTAVA extend J&J into AI-guided robotics.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-2%
Yahoo Finance
Aug 20th, 2026
J&J CEO signals double-digit growth by decade's end on new drug launches

Johnson & Johnson's chief executive says the company has a "line of sight to double-digit growth by the end of the decade", driven by three newer drugs: Icotyde, Inlexzo and Rybrevant. The pharmaceutical company spun off its healthcare division Kenvue in May 2023 to focus on pharmaceuticals and medical technology. The strategy appears to be working: J&J's share price has risen 55.5% over the past year, compared to 20.7% for the S&P 500. Second-quarter 2026 revenue climbed 6.6% year-over-year to $25.3 billion, primarily driven by its pharmaceutical segment. Tremfya, a drug for inflammatory bowel disease and psoriasis, saw sales jump 72.5% to $2 billion, whilst Darzalex reached $4.2 billion in sales.

Yahoo Finance
Aug 19th, 2026
Johnson & Johnson rises 57% in 12 months with near-zero correlation to S&P 500

Johnson & Johnson has gained 4.4% over the past five trading days whilst the S&P 500 slipped 0.5%. The stock is up 57.3% over the trailing twelve months. Over the past five years, JNJ's correlation to the S&P 500 has been just 0.16, meaning it moves largely independently of the broad market. This independence delivered an annualised return of 11.8% at 17.5% volatility, compared to the index's 13.2% at 17.2% volatility. The company's operational sales grew 5.6% in the second quarter of 2026, reaching $25.3 billion, even as STELARA declined 55.7% under biosimilar competition. TREMFYA grew 71% and now leads new-patient starts in both ulcerative colitis and Crohn's disease. Over the past year, on days when the S&P 500 fell, JNJ moved approximately 65% in the opposite direction.

Highly Capitalized
Aug 19th, 2026
J&J leads Delix's $85M Series C with right of first negotiation on neuroplasticity drug

Johnson & Johnson will lead an $85 million Series C for Delix Therapeutics at a $190 million pre-money valuation. The biotech develops non-hallucinogenic drugs to promote neuroplasticity in psychiatric patients. J&J's term sheet includes a right of first negotiation following Phase II data from Delix's lead compound, DLX-001. This positions J&J as first in line for potential acquisition discussions. Delix announced positive Phase II results in October 2025, showing rapid and durable reductions in depressive symptoms. The FDA cleared a Phase II design allowing patients to self-administer the compound at home. J&J brings relevant experience through Spravato, its FDA-approved nasal spray for treatment-resistant depression. Delix's at-home dosing model offers scalability that Spravato lacks. The financing has not yet closed.

Psychedelic Alpha
Aug 18th, 2026
Scoop: Johnson & Johnson to Lead Delix Therapeutics’ $85M Series C

Johnson & Johnson is set to lead neuroplastogen developer Delix Therapeutics’ $85M Series C round, according to documents reviewed by Psychedelic Alpha.

Yahoo Finance
Aug 18th, 2026
J&J wins FDA clearance for AI-powered MONARCH QUEST 3 robotic bronchoscopy system

Johnson & Johnson received FDA clearance for its MONARCH QUEST 3 bronchoscopy system, a software update introducing AI-powered tools for procedure planning and lung nodule segmentation to its robotic-assisted bronchoscopy platform. The clearance expands Johnson & Johnson's capabilities in minimally invasive diagnostics and treatment within its MedTech portfolio. New digital ecosystem features are designed to support broader adoption of robotic and AI-guided tools in hospital and clinical settings. The launch forms part of Johnson & Johnson's strategy to expand MedTech and robotic surgery as larger earnings drivers alongside its pharmaceutical business. The system enters a competitive market where Intuitive Surgical and Medtronic already operate in AI-guided surgical procedures.